Pharmacokinetic and pharmacodynamic rational for expanding the therapeutic landscape of psilocybin beyond depression

J. Mingardi, R. Molteni, F. Bifari

Pharmacological Research June 11, 2026 Peer reviewed DOI: 10.1016/j.phrs.2026.108290 via OpenAlex

Relevant Not relevant

Abstract

No abstract available from the source.

Tags

Psilocybin Depression economics Pharmacokinetics Pharmacodynamics Hallucinogen

Psilocybin's effects on obsessive-compulsive behaviors: A systematic review of preclinical and clinical evidence Psychedelics. • October 28, 2025 • via OpenAlex
Psilocybin - A Drug to be Considered for the Treatment of Anxiety and Depression in Cancer Patients Journal of Natural Remedies • July 31, 2024 • via OpenAlex
CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder Neuropsychopharmacology • July 7, 2026 • via OpenAlex
Mystical but Not Challenging Experiences Predict Symptom Improvement After Psilocybin for Treatment-Resistant OCD February 11, 2026 • via OpenAlex
PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial Palliative Medicine • January 30, 2026 • via OpenAlex

Comments

No comments yet.

Log in to comment